Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT05833724 is registered in ClinicalTrials.gov with Great Novel Therapeutics Biotech & Medicals Corporation as lead sponsor.

NCT NCT05833724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05833724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Lead sponsor
Great Novel Therapeutics Biotech & Medicals Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2024
Completion date
December 31, 2027
Enrollment
33 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory peripheral t-cell lymphoma